Immunotherapy plus chemotherapy before surgery for stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding an immunotherapy drug (sintilimab) to two different chemotherapy combinations before surgery can help shrink stomach cancer and improve outcomes. It is for people with locally advanced stomach cancer that can be removed with surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with locally advanced stomach cancer that can be surgically removed.
- You are generally well enough to carry out daily activities (ECOG score 0-1).
- You are willing to receive chemotherapy and immunotherapy before surgery.
- Your tumor has a specific genetic feature called deficient mismatch repair (dMMR).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a combination of chemotherapy and an immunotherapy drug before surgery helps shrink stomach cancer tumors and improve outcomes. The treatment is given in the neoadjuvant (before surgery) setting for stomach cancer that is locally advanced but not spread.
This trial tests a combination of two immunotherapy drugs (ipilimumab and sintilimab) with chemotherapy (modified XELOX) as a first treatment for stomach cancer that cannot be removed by surgery. The goal is to see if this combination can shrink the tumor enough to allow surgery later.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests whether adding an immunotherapy drug called sintilimab to chemotherapy and radiation before surgery can help shrink tumors and improve outcomes for people with gastroesophageal junction cancer. It is designed for patients who have not had previous treatment for this cancer.
This trial tests whether adding the immunotherapy drug Sintilimab to standard chemotherapy after surgery can help prevent stomach or gastroesophageal junction cancer from coming back. It's for people with high-risk or advanced stage cancer that has a specific genetic feature (dMMR or MSI-H).
This study tests a combination of an immunotherapy drug (tislelizumab) with two chemotherapy drugs (called the SOX regimen) given before surgery for locally advanced stomach cancer. The goal is to see if this treatment can shrink the tumor and make it easier to remove completely during surgery.
Hear when a new Neoadjuvant Chemotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.